Table 2

Analysis of primary outcome: CDI recurrence within 12 weeks

Placebo
(n=74)
Rifaximin
(n=77)
Risk difference
(95% CI, p values)
Main analysis: available case
 Primary outcome data available6169
 No recurrence43 (70.5%)58 (84.1%)
 Recurrence18 (29.5%)11 (15.9%)−13.7% (−28.1% to 0.7%,
p=0.06)
  • Number of participants with primary outcome data available is used as the denominator for CDI recurrence.

  • Risk difference/risk ratio and 95% CIs calculated using generalised estimating equations (with an exchangeable correlation matrix to account for hospital) using the Binomial family.

  • CDI, Clostridium difficile infection.